A Single-center, Open-label, Single-dose Phase I Study to Investigate the Absorption, Metabolism and Excretion of [14C]SH-1028 in Chinese Healthy Male Subjects
Overview
- Phase
- Phase 1
- Intervention
- [14C] SH-1028
- Conditions
- Healthy Male Volunteers
- Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
- Enrollment
- 6
- Locations
- 1
- Primary Endpoint
- The percentage of radioactive dose of [14C] radiolabelled SH-1028 recovered in urine, faeces and in total, up to Day 15.
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
This is a single-center, open-label, single-dose phase I study to investigate the absorption, metabolism and excretion of [14C] SH-1028 in healthy Chinese male subjects. The study will be conducted into two steps：Firstly, 2 subjects are enrolled in to participate in the pilot study to grope for the collection time of plasma, urine and feces sampling post-dose. Then, the collection time of blood and excreta samples (urine and feces) from the subsequent 2-4 subjects will be adjusted according to the pilot study.
Detailed Description
Subjects who had signed informed consent and meet inclusion criteria and no exclusion criteria are admitted to Phase I Clinical Unit two days prior to dosing (D-2). On the morning of Day 1 before dosing, subjects will be transferred to nuclear medical ward. And after an overnight fast of at least 10 h, subjects will receive a single oral dose of 200 mg (88 μCi) of \[14C\]SH-1028 as an oral suspension. Then, after two days of the dosing, subjects will be transferred back to Phase I Clinical Unit ward and confined to this unit until blood or excreta sampling and safety monitoring at the designated time points or intervals are complete.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Healthy male volunteers between the age of 18 to 50 years old；
- •Body weight \>=50 kg, Body mass index between 19 and 26 kg/m2 (including 19 and 26 kg/m2);
- •Normal physical findings, clinical laboratory values, vital signs and 12-lead ECG, or any abnormality that is non-clinically significant;
- •Male subjects of reproductive potential with partners will be instructed to, and must be willing to practice a highly effective method of birth control for the duration of the study and continuing 6 months after discontinuing treatment with the investigational product.;
- •Signing the informed consent forms by oneself;
- •Be able to communicate well with the researcher and be able to complete the trial in accordance with the program.
Exclusion Criteria
- •History of or current clinically significant cardio, pulmonary, endocrine, metabolism, renal, hepatic, gastrointestinal, dermatology, infection, hematology, neurological, mental disease or disorder;
- •Positive test for HBs-Ag, HCV-Ab, HIV-Ab, or syphilis antibody;
- •Long-QT syndrome or family history of it, or QTcF interval \> 450 mses;
- •Allergies, have allergies to drugs or foods; or have known allergies to the components of the drug;
- •Those who smoked daily \>5 sticks of cigarette 3 months prior to first dose or cannot give up smoking during study；
- •The weekly alcohol consumption was higher than 14 units of alcohol (1 unit=10ml or 8g absolute alcohol. 25 ml 40% liquor, 330ml 5% beers, 175ml 12% grape wine are equal to 1.0, 1.5 and 2.0 units of alcohol respectively) 3 months prior to screening period, or positive test for the alcohol breath test results during screening period；
- •Those have history of drug abuse or taking soft drug (i.e., marihuana); or the results of urine test in drugs were positive;
- •Participated in other clinical trials within 3 months before screening;
- •Received any drug within 14 days before taking the investigational drug;
- •Received any drugs that inhibit or induce the CYP450 enzyme (i.e., inducers- barbiturates, tegretol, phenytoin, rifampicin, hexadecadrol, rifabutin, rifapentini; inhibitors- SSRI-antidepressant, cimetidine, diltiazem, macrolides, verapamil, imidazoles- antifungal drugs) 30 days prior to screening period；
Arms & Interventions
[14C] SH-1028
Volunteers will receive 200 mg \[14C\] SH-1028 containing a nominal 88 μCi activity, administered by mouth, as a solution.
Intervention: [14C] SH-1028
Outcomes
Primary Outcomes
The percentage of radioactive dose of [14C] radiolabelled SH-1028 recovered in urine, faeces and in total, up to Day 15.
Time Frame: Day1 to Day 15
Quantitive analysis of whole radioactivity of excrement of orally administered \[14C\]SH-1028 in healthy volunteers to obtain the mass balance data and the main excretion pathway in human body.
The concentrations of SH-1028, Imp2 and Imp3 in plasma up to Day 15
Time Frame: Blood samples : - 0.5hrs, 1hrs, 2hrs, 3hrs, 4hrs, 6hrs, 8hrs, 12hrs, 24hrs, 48hrs, 72hrs, 120hrs, 168hrs, 216hrs, 264hrs and 336hrs
Quantitive analysis of the concentrations of SH-1028 and Imp2,Imp3 (Metabolites of SH-1028) in plasma using the validated LC-MS/MS to obtain pharmacokinetic data.
Types of adverse events
Time Frame: Baseline (Day-2) to Day 15
Types of adverse events assessed by CTCAE v5.0 that occurred during the trial
The percentage of radioactive dose of [14C] radiolabelled SH-1028 recovered in blood and in total, up to Day 15
Time Frame: Blood samples : - 0.5hrs, 1hrs, 2hrs, 3hrs, 4hrs, 6hrs, 8hrs, 12hrs, 24hrs, 48hrs, 72hrs, 120hrs, 168hrs, 216hrs, 264hrs and 336hrs
The distribution of \[14C\]SH-1028 in the whole blood and plasma and whole radioactive pharmacokinetics following the single orally administered \[14C\]SH-1028 in healthy male volunteers.
Proportion of different metabolites
Time Frame: Blood samples : - 0.5hrs, 1hrs, 2hrs, 3hrs, 4hrs, 6hrs, 8hrs, 12hrs, 24hrs, 48hrs, 72hrs, 120hrs, 168hrs, 216hrs, 264hrs and 336hrs
Proportion of different metabolites in healthy volunteers after oral administration of \[14C\]SH-1028